MENU
VCYT
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

VCYT stock forecast, quote, news & analysis

Veracyte Inc is a genomic diagnostics company... Show more

Industry: #Biotechnology
VCYT
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for VCYT with price predictions
Sep 22, 2026

VCYT in upward trend: price may jump up because it broke its lower Bollinger Band on September 16, 2026

VCYT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 29 of 36 cases where VCYT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where VCYT's RSI Indicator exited the oversold zone, 16 of 21 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 66 cases where VCYT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.

The Momentum Indicator moved above the 0 level on September 22, 2026. You may want to consider a long position or call options on VCYT as a result. In 74 of 105 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.

The Moving Average Convergence Divergence (MACD) for VCYT just turned positive on September 21, 2026. Looking at past instances where VCYT's MACD turned positive, the stock continued to rise in 40 of 50 cases over the following month. The odds of a continued upward trend are 80%.

Following a +8.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where VCYT advanced for three days, in 204 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VCYT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

The Aroon Indicator for VCYT entered a downward trend on September 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.511) is normal, around the industry mean (60.700). P/E Ratio (30.979) is within average values for comparable stocks, (144.546). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.432). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (5.583) is also within normal values, averaging (9.775).

The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating fairly steady price growth. VCYT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 75 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 96 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VCYT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are IQVIA Holdings (NYSE:IQV), Illumina (NASDAQ:ILMN), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 19.68B. The market cap for tickers in the group ranges from 27 to 4.39T. MKYSF holds the highest valuation in this group at 4.39T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was 4%. For the same Industry, the average monthly price growth was 6%, and the average quarterly price growth was 55%. GRAL experienced the highest price growth at 43%, while ADVB experienced the biggest fall at -21%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was 7%. For the same stocks of the Industry, the average monthly volume growth was 11% and the average quarterly volume growth was 25%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 61
Price Growth Rating: 41
SMR Rating: 78
Profit Risk Rating: 90
Seasonality Score: -24 (-100 ... +100)
View a ticker or compare two or three
VCYT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a company that discovers, develops and commercializes molecular diagnostic solutions

Industry MedicalSpecialties

Industry
Biotechnology
Address
6000 Shoreline Court
Phone
+1 650 243-6300
Employees
755
Web
https://www.veracyte.com
VCYT in upward trend: price may jump up because it broke its lower Bollinger Band on September 16, 2026